Nemesis Bioscience Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Bankr. Admin/​Reorg

Nemesis Bioscience General Information

Description

Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies develop bacterial cybernetics for applications including the reversal of antibiotic resistance and for their clinical, veterinary, and industrial delivery, enabling therapeutics to get existing antibiotics to work again, prevent the spread of resistance genes and so also protect the efficacy of new antibiotics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • Building B270
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nemesis Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Bankruptcy: Admin/Reorg 01-Feb-2023 Completed Bankruptcy: Admin/Reorg
6. Later Stage VC 01-Jan-2021 00.000 Completed Generating Revenue
5. Grant 27-Mar-2019 00000 00.000 Completed Generating Revenue
4. Early Stage VC 15-Jun-2018 00.000 00.000 00.000 Completed Generating Revenue
3. Seed Round 01-Nov-2017 00000 00.000 Completed Generating Revenue
2. Grant 01-Aug-2015 $63.3K $465K Completed Startup
1. Seed Round 15-Jun-2015 $465K $465K Completed Startup
To view Nemesis Bioscience’s complete valuation and funding history, request access »

Nemesis Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Preferred 0,000 00.000000 000.00 000.00 00 000.00 0.000
A Preferred 0,000 00.000000 0000.0 0000.0 00 0000.0 00.000
A Ordinary 3,752 $0.013371 $149.3 $149.3 1x $149.3 6.26%
To view Nemesis Bioscience’s complete cap table history, request access »

Nemesis Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies
Biotechnology
Cambridge, United Kingdom
9 As of 2023
00.000
0000000000.

00000

ing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000000000000
Paris, France
00 As of 0000
000.00
00000000000 000.00

00000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullam
0000000000000
Ness Ziona, Israel
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nemesis Bioscience Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eligo Bioscience Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
BiomX Formerly VC-backed Ness Ziona, Israel 00 000.00 000000000 000.00
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom 00 000.00 00000000000 000.00
Adimab Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
F2G Venture Capital-Backed Manchester, United Kingdom 00 00000 0000000000 0 00000
You’re viewing 5 of 44 competitors. Get the full list »

Nemesis Bioscience Executive Team (3)

Name Title Board Seat Contact Info
Frank Massam Ph.D Co-Founder & Chief Executive Officer
You’re viewing 1 of 3 executive team members. Get the full list »

Nemesis Bioscience Board Members (3)

Name Representing Role Since
Alastair Riddell Self Board Member 000 0000
Yoshinori Yamano Self Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Nemesis Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nemesis Bioscience FAQs

  • When was Nemesis Bioscience founded?

    Nemesis Bioscience was founded in 2014.

  • Who is the founder of Nemesis Bioscience?

    Frank Massam Ph.D, Conrad Lichtenstein Ph.D, and Yoshikazu Mikawa Ph.D are the founders of Nemesis Bioscience.

  • Who is the CEO of Nemesis Bioscience?

    Frank Massam Ph.D is the CEO of Nemesis Bioscience.

  • Where is Nemesis Bioscience headquartered?

    Nemesis Bioscience is headquartered in Cambridge, United Kingdom.

  • What is the size of Nemesis Bioscience?

    Nemesis Bioscience has 9 total employees.

  • What industry is Nemesis Bioscience in?

    Nemesis Bioscience’s primary industry is Biotechnology.

  • Is Nemesis Bioscience a private or public company?

    Nemesis Bioscience is a Private company.

  • What is Nemesis Bioscience’s current revenue?

    The current revenue for Nemesis Bioscience is 000000.

  • How much funding has Nemesis Bioscience raised over time?

    Nemesis Bioscience has raised $3.61M.

  • Who are Nemesis Bioscience’s competitors?

    Eligo Bioscience, BiomX, NovaBiotics, Adimab, and F2G are some of the 44 competitors of Nemesis Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »